Lama Nazer1, Mohammad Al-Shaer, Feras Hawari. 1. Department of Pharmacy, King Hussein Cancer Center, Queen Rania Al-Abdallah Street, P.O.Box 1269, Amman, 11941, Jordan, lnazer@khcc.jo.
Abstract
BACKGROUND: Cancer patients are at high risk for developing sepsis. To our knowledge, there are no studies that evaluated the type of medications utilized and the associated cost in cancer patients with severe sepsis and septic shock. OBJECTIVE: To describe the drug utilization pattern and drug cost in the treatment of cancer patients with severe sepsis and septic shock. SETTING: 12-bed medical/surgical intensive care unit (ICU) of a comprehensive teaching cancer center. METHODS: A retrospective cohort study of cancer patients with severe sepsis or septic shock who were treated in the ICU between January and December, 2010. The ICU sepsis database was used to identify patients. The patient demographics and characteristics were recorded. In addition, the number and type of prescribed medications, total cost for each medication, type of infection, and culture results were determined. MAIN OUTCOME MEASURE: The main outcomes were the type of medication classes utilized and the cost of the medications. RESULTS: During the study period, 116 cases were identified. Upon presentation, the mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 21.8 (SD ± 7.8), 30 (25.9 %) patients had neutropenia, and 94 (81 %) had positive cultures. The total cost of the medications prescribed for this cohort of patients was 291,030 Euro. The mean number of medications prescribed per patient and the mean total cost per patient were 11.7 (SD ± 4.7) and 2,509 Euro (SD ± 2,844), respectively. The most commonly prescribed medication classes were acid suppressive therapy, glycopeptides, penicillins/cephalosporins and vasopressors prescribed in 113 (97 %), 104 (89.7 %), 103 (88.9 %), and 102 (88 %) patients, respectively. The highest medication costs were associated with antifungals (mean 1,288 Euro/patient) and colony stimulating factors (mean 829 Euro/patient), prescribed in 55 (47.4 %) and 37 (31.9 %) patients, respectively. Medication costs were higher in non-survivors, compared to survivors (3,664 Euro vs. 1,430 Euro, p = 0.0001), and in patients with positive cultures, compared to patients with negative cultures (3,198 Euro vs. 1,865 Euro, p = 0.0004). CONCLUSION: In cancer patients with severe sepsis and septic shock, multiple medications are prescribed which are associated with high cost.
BACKGROUND:Cancerpatients are at high risk for developing sepsis. To our knowledge, there are no studies that evaluated the type of medications utilized and the associated cost in cancerpatients with severe sepsis and septic shock. OBJECTIVE: To describe the drug utilization pattern and drug cost in the treatment of cancerpatients with severe sepsis and septic shock. SETTING: 12-bed medical/surgical intensive care unit (ICU) of a comprehensive teaching cancer center. METHODS: A retrospective cohort study of cancerpatients with severe sepsis or septic shock who were treated in the ICU between January and December, 2010. The ICU sepsis database was used to identify patients. The patient demographics and characteristics were recorded. In addition, the number and type of prescribed medications, total cost for each medication, type of infection, and culture results were determined. MAIN OUTCOME MEASURE: The main outcomes were the type of medication classes utilized and the cost of the medications. RESULTS: During the study period, 116 cases were identified. Upon presentation, the mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 21.8 (SD ± 7.8), 30 (25.9 %) patients had neutropenia, and 94 (81 %) had positive cultures. The total cost of the medications prescribed for this cohort of patients was 291,030 Euro. The mean number of medications prescribed per patient and the mean total cost per patient were 11.7 (SD ± 4.7) and 2,509 Euro (SD ± 2,844), respectively. The most commonly prescribed medication classes were acid suppressive therapy, glycopeptides, penicillins/cephalosporins and vasopressors prescribed in 113 (97 %), 104 (89.7 %), 103 (88.9 %), and 102 (88 %) patients, respectively. The highest medication costs were associated with antifungals (mean 1,288 Euro/patient) and colony stimulating factors (mean 829 Euro/patient), prescribed in 55 (47.4 %) and 37 (31.9 %) patients, respectively. Medication costs were higher in non-survivors, compared to survivors (3,664 Euro vs. 1,430 Euro, p = 0.0001), and in patients with positive cultures, compared to patients with negative cultures (3,198 Euro vs. 1,865 Euro, p = 0.0004). CONCLUSION: In cancerpatients with severe sepsis and septic shock, multiple medications are prescribed which are associated with high cost.
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Onnen Moerer; Alexandra Schmid; Michael Hofmann; Anja Herklotz; Konrad Reinhart; Karl Werdan; Heinz Schneider; Hilmar Burchardi Journal: Intensive Care Med Date: 2002-08-17 Impact factor: 17.440
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Feras I Hawari; Taghreed I Al Najjar; Luna Zaru; Wa'ed Al Fayoumee; Samer H Salah; Mohammad Z Mukhaimar Journal: Crit Care Med Date: 2009-06 Impact factor: 7.598
Authors: Ana M C Sogayar; Flavia R Machado; Alvaro Rea-Neto; Amselmo Dornas; Cintia M C Grion; Suzana M A Lobo; Bernardo R Tura; Carla L O Silva; Ruy G R Cal; Idal Beer; Vilto Michels; Jorge Safi; Marcia Kayath; Eliezer Silva Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981
Authors: Robert J Weber; Sandra L Kane; Vincent A Oriolo; Melissa Saul; Susan J Skledar; Joseph F Dasta Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Bogdan Tiru; Ernest K DiNino; Abigail Orenstein; Patrick T Mailloux; Adam Pesaturo; Abhinav Gupta; William T McGee Journal: Pharmacoeconomics Date: 2015-09 Impact factor: 4.981
Authors: Aseel K AbuSara; Deema H Abdelrahman; Khader I Habash; Mohammad H Al-Shaer; Jennifer Le; Lama H Nazer Journal: Pharmacol Res Perspect Date: 2022-02
Authors: Andrew Donkor; Vivian Della Atuwo-Ampoh; Frederick Yakanu; Eric Torgbenu; Edward Kwabena Ameyaw; Doris Kitson-Mills; Verna Vanderpuye; Kofi Adesi Kyei; Samuel Anim-Sampong; Omar Khader; Jamal Khader Journal: Support Care Cancer Date: 2022-04-25 Impact factor: 3.359
Authors: Karin Thursky; Senthil Lingaratnam; Jasveer Jayarajan; Gabrielle M Haeusler; Benjamin Teh; Michelle Tew; Georgina Venn; Alison Hiong; Christine Brown; Vivian Leung; Leon J Worth; Kim Dalziel; Monica A Slavin Journal: BMJ Open Qual Date: 2018-07-06